Navigation Links
Cell Therapeutics Announces Removal of the Partial Clinical Hold on Tosedostat
Date:1/2/2014

which could materially and/or adversely affect actual future results and the trading price of CTI's securities. Specifically, the risks and uncertainties that could affect the development of tosedostat include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with tosedostat in particular including, without limitation, the potential failure of tosedostat to prove safe and effective as determined by the FDA and/or the European Medicines Agency; determinations by regulatory, patent, and administrative governmental authorities; competitive factors; technological developments; costs of developing and producing tosedostat; and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission, including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. CTI can give no assurances that any results or events projected or contemplated by its forward-looking statements will in fact occur and CTI cautions you not to place undue reliance on these statements. CTI undertakes no duty to update these forward-looking statements to reflect any future events, developments or otherwise.

References:

  1. American Cancer Society, Cancer Facts & Figures 2013. Available at http://tinyurl.com/kl6vs5h . Accessed June 2013.
  2. The Leukemia and Lymphoma Society, Acute Myeloid Leukemia, Rev. 2011. Available at http://tinyurl.com/d72ycja. Accessed February 2013.

Contacts:
Monique Greer
+1 206-272-4343
mgreer@ctiseattle.com  

Ed Bell
+1 206-282-7100
ebell@ctiseattle.com  

In Europe:
CTI Life Sciences Limite
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... plc (NYSE: ACT ), a leading global pharmaceutical company, ... of Actavis, will provide an overview and update of the ... Conference in Rancho Palos Verdes, Calif. ... The presentation will take place on Wednesday, June 10, 2015 ... Rancho Palos Verdes, Calif.  To access a ...
(Date:6/3/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/t3kkhg/the_future_of ... "The Future of Pharmaceutical Outsourcing" report to ... a desperate need to develop better drugs with ... have been increasingly utilizing external resources to increase ... streamlining their internal operation. Their outsourcing demands and ...
(Date:6/3/2015)... , June 3, 2015 MEDTEC China South 2015 came ... of MEDTEC China 2015, MEDTEC China South has been recognized ... out as a key event for the medical device manufacturing ... years of challenges, this year marks the successful return of the ... after the event first debuted there in 2005. ...
Breaking Medicine Technology:Actavis to Present at the Goldman Sachs 36th Annual Global Healthcare Conference 2The Future of Pharmaceutical Outsourcing: 2015 Report 2MEDTEC Successfully Returns to Southern China 2MEDTEC Successfully Returns to Southern China 3
... ACR70 Results, SOUTH SAN FRANCICSO, Calif., Dec. ... today announced that its oral syk,kinase inhibitor, R788 ... Rheumatoid Arthritis (RA) patients in a,recently completed Phase ... and 150mg po bid (orally, twice daily), showed ...
... BioForm Medical,Inc. (Nasdaq: BFRM ) today announced ... of nasolabial fold treatments,reporting higher patient satisfaction with ... either Juvederm(TM) or Perlane(R). The,results of this study ... of,the Journal of Dermatologic Surgery, a peer-reviewed publication ...
Cached Medicine Technology:Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study 2Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study 3Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study 4Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study 5Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study 6Radiesse Provides Greater Patient Satisfaction Than Either Juvederm or Perlane as Reported in a 205-Patient Clinical Trial Published in the Journal of Dermatologic Surgery 2Radiesse Provides Greater Patient Satisfaction Than Either Juvederm or Perlane as Reported in a 205-Patient Clinical Trial Published in the Journal of Dermatologic Surgery 3Radiesse Provides Greater Patient Satisfaction Than Either Juvederm or Perlane as Reported in a 205-Patient Clinical Trial Published in the Journal of Dermatologic Surgery 4Radiesse Provides Greater Patient Satisfaction Than Either Juvederm or Perlane as Reported in a 205-Patient Clinical Trial Published in the Journal of Dermatologic Surgery 5Radiesse Provides Greater Patient Satisfaction Than Either Juvederm or Perlane as Reported in a 205-Patient Clinical Trial Published in the Journal of Dermatologic Surgery 6
(Date:6/3/2015)... June 03, 2015 AvePoint, ... and devices, announced today that it has won the ... and Content. The company was honored among a global ... in innovation and implementation of customer solutions based on ... of the Year Awards – including the 2014 Microsoft ...
(Date:6/3/2015)... Follow us on LinkedIn ... disease treatment on account of their better mode of ... as rheumatoid arthritis. The industry is expected to witness ... molecule drugs to biopharmaceuticals over the coming years. The ... gene therapies, and recombinant proteins has attracted industry players ...
(Date:6/3/2015)... Newark, New Jersey (PRWEB) June 03, 2015 ... chosen by Diversity MBA Magazine as one of the nation’s ... ranked Horizon BCBSNJ No. 6 among its national list of ... ranked Horizon BNCBSNJ as the No. 1 Regional Company. ... been honored by Diversity MBA Magazine for its diverse workplace ...
(Date:6/3/2015)... 03, 2015 Justina Molzon, MS Pharm, ... at DIA’s upcoming Annual Meeting. DIA’s Global Inspire Award ... level of excellence, and commitment to service on a ... Excellence in Service Award that recognizes the “Member of ... DIA volunteer and who has contributed to the advancement ...
(Date:6/3/2015)... Researchers at the University of Western Australia ... the tried-and-true marker mesothelin is the best option available. ... research. Click here to read it now. ... Related Diseases say, even though a mesothelin test can ... to fibulin-3 for identifying mesothelioma. , “Preliminary results ...
Breaking Medicine News(10 mins):Health News:AvePoint Wins 2015 Microsoft Partner of the Year Award for Collaboration and Content 2Health News:AvePoint Wins 2015 Microsoft Partner of the Year Award for Collaboration and Content 3Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 4Health News:Horizon Blue Cross Blue Shield of New Jersey Named a 2015 Best Place for Diverse Managers and Women to Work by Diversity MBA Magazine 2Health News:Former FDA Official and U.S. Public Health Service Officer to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 2Health News:Former FDA Official and U.S. Public Health Service Officer to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 3Health News:Analysis Reveals Gold Standard Mesothelioma Biomarker Still the Best, According to Surviving Mesothelioma 2
... Speaker Nancy Pelosi,delivered remarks this morning at the ... members of Congress, and hundreds of,children and seniors. ... full,funding of the State Children,s Health Insurance Program ... ask me what the three most important issues ...
... BETHESDA, Md., Sept. 6 Montana native and health ... Center Billings, MT, has been,installed to the post ... Health Centers (NACHC). Ceremonies took place at NACHC,s ... in Dallas, TX,which drew thousands of health center ...
... to make open-heart,surgery a minimally invasive procedure ... of Health Bioengineering Research Partnership award.,Professor Pierre ... surgeon Pedro del Nido, M.D., at Children,s ... Inc. (Van Nuys,CA) will collaborate to develop ...
... finds it brings the patient real benefit, too , ... partners with Alzheimer,s disease report better physical health if ... shows. , "Preserving the health of spouse caregivers through ... disease, as caregivers who are in poor health are ...
... 6 In response to,reports about the potential closure ... today reassured employees that the,civil section of the facility ... of closing the civil section of Warren,State Hospital and ... in,which residents and counties have come to depend," said ...
... on most common cause of inherited mental ... impairment and Parkinson-like syndrome, SAN FRANCISCO, ... California, Davis, School of Medicine and the M.I.N.D.,Institute, in collaboration ... Interdisciplinary Research Consortium grant from,the National Institutes of Heath, the ...
Cached Medicine News:Health News:Pelosi: SCHIP Bill a Giant Step for America's Children 2Health News:Montana Health Care Leader Elected Board Chair of National Association 2Health News:Minimally Invasive Heart Surgery Research Wins N.I.H. Award 2Health News:Counseling Boosts Alzheimer's Caregivers' Health 2Health News:PA Secretary of Public Welfare Responds to Warren State Hospital Closure Rumors 2Health News:$21.8 Million NIH Grant for Fragile X Research 2Health News:$21.8 Million NIH Grant for Fragile X Research 3Health News:$21.8 Million NIH Grant for Fragile X Research 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: